NCT00343460 2026-03-02
APF530 or Aloxi (Palonosetron Hydrochloride) Combined With Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Cancer
Heron Therapeutics
Phase 3 Completed
Clinical Trials
22 trialsNCT06007586 2025-12-04
Prevention and Treatment of CINV Caused by TC Regimen in Gynecological Malignant Tumor Patients
Sichuan Cancer Hospital and Research Institute
Phase 3 Completed
NCT05564286 2024-02-06
Triple Antiemetic Regimen for Chemoradiotherapy in Cervical Cancer or Nasopharyngeal Cancer
Shantou University Medical College
Phase 3 Completed
NCT03674294 2023-02-08
CINV
Sun Yat-sen University
Phase 3 Completed
NCT01363479 2021-09-22
An Efficacy and Safety Study of Oral and Intravenous Palonosetron for the Prevention of Nausea and Vomiting
Helsinn Healthcare SA
Phase 3 Completed
NCT01661335 2021-03-23
Efficacy of Aprepitant (Emend®) in Children
University of Oklahoma
Phase 3 Completed
NCT00553059 2020-10-09
Palonosetron and Dexamethasone With or Without Dronabinol in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy For Cancer
M.D. Anderson Cancer Center
Phase 3 Completed
NCT03403712 2020-06-01
A Study to Assess the Safety and the Efficacy of IV Fosnetupitant/Palonosetron (260 mg/0.25 mg) Combination Compared to Oral Netupitant/Palonosetron (300 mg/0.5 mg) Combination for the Prevention of CINV in AC Chemotherapy in Women With Breast Cancer
Helsinn Healthcare SA
Phase 3 Completed
NCT00016380 2020-04-03
Ondansetron With/Out Dexamethasone to Prevent Vomiting in Patients Receiving Radiation to the Upper Abdomen
Canadian Cancer Trials Group
Phase 3 Completed
NCT04201769 2020-04-03
LUNG-NEPA
Consorzio Oncotech
Phase 3 Unknown
NCT02557035 2018-06-20
An Efficacy and Safety Study of Intravenous Palonosetron Administered as an Infusion and as a Bolus for the Prevention of Nausea and Vomiting
Helsinn Healthcare SA
Phase 3 Completed
NCT00601172 2018-01-17
A Study Of IV Casopitant For The Prevention Of Chemotherapy Induced Nausea And Vomiting.
GlaxoSmithKline
Phase 3 Completed
NCT00431236 2017-08-22
A Study of the Drug Casopitant for the Prevention of Nausea Caused By Cisplatin-Based Highly Emetogenic Chemotherapy
GlaxoSmithKline
Phase 3 Completed
NCT02203253 2016-08-24
Efficacy of Thalidomide in Preventing Chemotherapy-induced Delayed Nausea and Vomiting
China Medical University, China
Phase 3 Completed
NCT01135550 2016-05-05
Low Dose Versus Usual Dose Dexamethasone for Symptom Control in Children Undergoing Cranial or Craniospinal Radiation
The Hospital for Sick Children
Phase 3 Terminated
NCT00475085 2015-11-10
Prevention of Delayed Nausea A Phase III Double-Blind Placebo-Controlled Clinical Trial
University of Rochester
Phase 3 Completed
NCT01074697 2015-04-24
GAND-emesis
Odense University Hospital
Phase 3 Completed
NCT00891761 2015-04-17
A Study of IV Casopitant for the Prevention of Nausea and Vomiting Caused By Cisplatin-Based Highly Emetogenic Chemotherapy
GlaxoSmithKline
Phase 3 Withdrawn
NCT01339260 2014-11-26
An Efficacy and Safety Study of Oral Netupitant and Palonosetron for the Prevention of Nausea and Vomiting
Helsinn Healthcare SA
Phase 3 Completed
NCT00869973 2013-01-23
Aprepitant in the Prevention of Delayed Emesis Induced by Cyclophosphamide Plus Anthracyclines in Breast Cancer Patients
S. Maria Hospital, Terni
Phase 3 Terminated
NCT00003213 2012-07-11
Drugs to Reduce the Side Effects of Chemotherapy
Swiss Cancer Institute
Phase 3 Completed
NCT00152867 2012-06-28
Dexamethasone Study: Impact on Quality of Life of Continuing Dexamethasone Following Emetogenic Chemotherapy
University Health Network, Toronto
Phase 3 Completed